Latest News

Hygiene Poverty and the Overlooked Toileting Needs of Women

Hygiene Poverty and the Overlooked Toileting Needs of Women

If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

read more

Latest News

Freeze-Dried Does Not Mean Pathogen-Free

Freeze-Dried Does Not Mean Pathogen-Free

Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Why a New Era of Medical Innovation is Taking Shape

Why a New Era of Medical Innovation is Taking Shape

Over the next decade, modern medicine is poised to undergo a redefinition that has not been seen in generations. The surge in innovation, transformational scientific discoveries and rapidly maturing technologies is redefining patient outcomes. The biotech industry is...

read more
Summary: England Rare Diseases Action Plan 2026

Summary: England Rare Diseases Action Plan 2026

The England Rare Diseases Action Plan 2026 outlines how the Department of Health and Social Care and partner organisations are delivering commitments under the UK Rare Diseases Framework to improve outcomes for people living with rare conditions in England. The report...

read more
ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC

ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC

At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...

read more
Why a New Era of Medical Innovation is Taking Shape

Why a New Era of Medical Innovation is Taking Shape

Over the next decade, modern medicine is poised to undergo a redefinition that has not been seen in generations. The surge in innovation, transformational scientific discoveries and rapidly maturing technologies is redefining patient outcomes. The biotech industry is...

read more
Summary: England Rare Diseases Action Plan 2026

Summary: England Rare Diseases Action Plan 2026

The England Rare Diseases Action Plan 2026 outlines how the Department of Health and Social Care and partner organisations are delivering commitments under the UK Rare Diseases Framework to improve outcomes for people living with rare conditions in England. The report...

read more
ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC

ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC

At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Global Funding Shifts Redraw Life Sciences Innovation Map

Global Funding Shifts Redraw Life Sciences Innovation Map

The life sciences sector is experiencing a fundamental reshaping of its innovation geography as funding pressures, policy shifts, and geopolitical tensions redraw the competitive landscape across continents. While research funding constraints in the United States...

read more
Medical Bankruptcy: The Hidden Cost of U.S. Health Care

Medical Bankruptcy: The Hidden Cost of U.S. Health Care

My wife underwent major surgery in December 2025. She remained 10 days in a Charlotte, NC, hospital and was then for several weeks supported at home by visiting nurses, a physical therapist and a dietician. We just saw the bill: The hospital and participating doctors...

read more
Pregnancy, the Brain, and the Nervous System

Pregnancy, the Brain, and the Nervous System

Pregnancy, the Brain, and the Nervous System: A Holistic Perspective on Perinatal Mental Health Pregnancy is often framed as a joyful milestone, yet from a clinical and neurobiological standpoint, it is one of the most significant periods of transformation a human...

read more

Further News

New Approach Methodologies: What Regulators Now Accept

New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...

Evaluating Retrieval Systems for Clinical AI

Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...

Women-Led Biotech Is Outperforming. Why Is Capital Lagging?

A new therapeutic can take a decade. Often hundreds of millions of dollars. Regulators checking the work at every stage along the way. So when a category of founders consistently delivers better returns on less capital, you'd expect investment patterns to reflect...

CSRD Reporting: What Has Changed for European Biotech

The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...

Microalgae Biomaterials: Where the Carbon Math Holds, and Where it Fails

A research team at the University of Colorado Boulder took a marine dinoflagellate called Pyrocystis lunula, mixed it into 4 wt% sodium alginate, crosslinked the gel ionically in calcium chloride, and extruded it through a Cellink BIO X bioprinter into printed grids...

NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave

NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...

Receptor.AI and Sethera Partner on AI-Guided Peptide Drug Discovery

Receptor.AI and Sethera Therapeutics Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Collaboration combines Sethera's proprietary enzymatic polymacrocyclisation and trillion-scale encoded screening with Receptor.AI's physics-based...

Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon

Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...

Ziltivekimab ZEUS Trial: What the Null Result Means

The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...

How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy

For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.